Dual antidepressants

PreclinicalSmall molecule

Eli Lilly

Dual antidepressants is one of 36 small molecule programs targeting Sexual Dysfunction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sexual DysfunctionActive, not recruiting

Sexual DysfunctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Sexual Dysfunction

#DrugCompanyPhaseTrials

Cymbalta

Alnylam Pharmaceuticals

Approved

1 2

Crestor

AstraZeneca

Approved

1 3

Viibryd

AbbVie

Approved

1 4

Estrace

Buspar

Viagra

VViatris Specialty LLC

Approved

2 7

Requip Xl

GGlaxo Dba Glaxosmithkline

Approved

1 8

Abilify

Otsuka

Approved

1 9

Tricor

JJagotec

Approved

1 10

Zoloft

VViatris Specialty LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sexual Dysfunction1 trial

Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months

Completed· Eli Lilly logo

Eli Lilly··NCT00561509·1,626 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dual antidepressants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual antidepressants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual antidepressants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

Dual antidepressants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sexual Dysfunction1 trial

References

Drug Info

Quick Facts

Related News